Glycobac, LLC

Laramie, WY · Biotech · Private

Engineered insect cell lines that produce glycoproteins with removable sugar structures for structural biology research and therapeutic protein production

Claim this profile

Follows are private to you and power your alerts

Updated · glycobac.com

Sector
Biotech
Headquarters
Laramie, WY
Total capital
$1.4M
Federal grants
$1.4M
4 awards · 2016–2020
Rank in peer group#9 of 18
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
2 pending · first 2022
Rank in peer group#8 of 18

Capital timeline

20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $1.4M$446K$493K$217K$225K
20162017201820192020FEDERAL ↑EQUITY ↓Cumulative $1.4M$446K$493K$217K$225K

Latest events

  • Federal grantHealth and Human S · Phase I · Insect cell lines for glycoprotein structural biology and mannose-dependent protein drugs$225K
  • Federal grantHealth and Human S · Phase I · Engineering a new insect cell line for human-type protein glycosylation$217K
  • Federal grantHealth and Human S · Phase II · Glycoengineered insect cells for commercial biologics manufacturing$493K
  • Federal grantHealth and Human S · Phase II · Glycoengineered insect cells for commercial biologics manufacturing$446K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 18 peers

Line = median

Biotech · Material

  • Federal grants#9 · top 50%
  • Granted patents#8 · top 44%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 3
  • PendingVirus-free Cell Lines And Methods For Obtaining SameUSPTOApplication 17931200
  • GrantedVirus-free Cell Lines And Methods For Obtaining SameUSPTOUS 11,473,055
  • PendingVirus-free Cell Lines And Methods For Obtaining SameUSPTOApplication PCTUS2016059857
  • CELETRIX, LLCSimilar federal contract value in Biotech · null in contracts
  • Myeloid TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Cardior PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • ZENOPHARM, LLCSimilar federal contract value in Biotech · null in contracts
  • OMNIOX INCSimilar federal contract value in Biotech · null in contracts
  • IMMUSOFT CORPSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .